Paper Details

  1. Home
  2. Paper Details

[Pharmacovigilance update].

Author: Abo LohaChristopher, LivioFrançoise

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review summarizes key pharmacovigilance updates from 2018, including recommendations against using quinolones for mild or moderately severe infections, the increased risk of new primary malignancies associated with denosumab in cancer patients, and the increased risk of meningioma with high-dose cyproterone. The review also highlights the risks of using Saccharomyces boulardii in frail patients, ulipristal's risk of hepatotoxicity, and the early withdrawal of daclizumab from the market due to outweighing risks.
Paper Details　
Original Abstract of the Article :
The main pharmacovigilance updates in 2018 are reviewed. Quinolones : no longer recommended for mild or moderately severe infections. Denosumab in cancer patients: increased risk of new primary malignancies. Cyproterone : increased risk of meningioma at high dose. Saccharomyces boulardii : risk of f...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/30629378

データ提供：米国国立医学図書館（NLM）

Pharmacovigilance: A Constant Watch for Safety in the Desert of Medications

The field of pharmacovigilance, like a vigilant sentinel in the desert of medications, constantly monitors for safety concerns and potential risks. This article provides an overview of key pharmacovigilance updates from 2018, highlighting changes in recommendations for various medications and alerting the medical community to emerging safety signals. The authors highlight specific concerns related to quinolones, denosumab, cyproterone, Saccharomyces boulardii, ulipristal, daclizumab, boosted antiretrovirals, dolutegravir, and drospirenone-containing pills.

Navigating the Shifting Sands of Medication Safety: Staying Informed

The information presented in this article is crucial for healthcare professionals, patients, and researchers alike. By staying informed about pharmacovigilance updates, we can collectively navigate the shifting sands of medication safety and ensure the safe and effective use of medicines.

Staying Informed in the Desert of Medications: A Guide to Safety

It's essential to stay informed about potential risks and changes in medication recommendations. Engaging in open communication with healthcare professionals and staying up-to-date on pharmacovigilance updates can help ensure medication safety and minimize potential complications.

Dr. Camel's Conclusion

The desert of medications is constantly evolving, with new discoveries and potential risks emerging all the time. Pharmacovigilance serves as a vital compass, guiding us through the complexities of medication safety and ensuring that our journey through the desert is safe and effective.

Date :
  1. Date Completed 2019-06-24
  2. Date Revised 2019-06-24
Further Info :

Pubmed ID

30629378

DOI: Digital Object Identifier

RMS0632-0633-022

SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.